TZ-2 is a research-grade synthetic peptide supplied as a lyophilized powder for use in controlled laboratory settings. The compound is a dual glucose-dependent insulinotropic polypeptide (GIP) and incretin receptor agonist that has been the subject of significant scientific inquiry in metabolic pathway research. Structurally, TZ-2 is a 39-amino acid linear peptide incorporating a C20 fatty diacid moiety conjugated via a linker to a lysine residue, enabling prolonged activity in experimental systems through non-covalent albumin association within assay media.
In cell-based reporter assays, TZ-2 has demonstrated potent agonism at both GIP and incretin receptor subtypes, enabling researchers to investigate the consequences of simultaneous dual-receptor engagement on intracellular signaling cascades — including cAMP generation, beta-arrestin recruitment, and ERK phosphorylation dynamics. Published work has applied this compound to cellular models of pancreatic islet biology, hypothalamic neurocircuitry, and adipocyte differentiation, reflecting its utility across a broad range of metabolic research applications.
Each vial is accompanied by analytical data confirming sequence identity via mass spectrometry and purity via reverse-phase HPLC. All laboratory personnel handling this compound should observe standard safety protocols. This product is sold exclusively for research purposes and is not intended for human or veterinary use under any circumstances.
FDA Disclaimer
The information presented on this website has not been evaluated by the U.S. Food and Drug Administration. No content on this site, nor any product listed, is intended to diagnose, treat, cure, or prevent any disease or medical condition.
All products are supplied solely as laboratory research reagents and are not for human consumption. Ares Research does not supply products to patients and makes no representations regarding therapeutic or medical use.
Ares Research operates as a chemical supplier only. It is not a compounding pharmacy and does not function as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.
